Status:
COMPLETED
Peripheral Muscle Microcirculation and Exercise-induced Blood Flow Distribution in Pulmonary Arterial Hypertension
Lead Sponsor:
Laval University
Conditions:
Pulmonary Arterial Hypertension
Eligibility:
All Genders
Phase:
NA
Brief Summary
Pulmonary artery hypertension (PAH) is a rare, severe disease, characterized by a progressive increase in pulmonary vascular resistance ultimately leading to right ventricular (RV) failure and prematu...
Detailed Description
Pulmonary artery hypertension (PAH) is a rare, severe disease, characterized by a progressive increase in pulmonary vascular resistance ultimately leading to right ventricular (RV) failure and prematu...
Eligibility Criteria
Inclusion
- WHO functional class II-III idiopathic PAH patients;
- WHO functional class II-III PAH-SSc patients with hemodynamic assessment \<6 months;
- sedentary healthy subjects;
- subjects with limited SSc (without PAH) individually matched for age, gender, height and weight.
Exclusion
- unstable clinical condition (e.g. recent syncope, WHO functional class IV);
- a six-minute walked distance \< 300 meters during routine follow-up at the pulmonary hypertension clinic;
- left ventricular ejection fraction \< 40%;
- restrictive (lung fibrosis on CT scan or total lung capacity \< 80% of predicted) or obstructive lung disease (FEV1/FVC \< 70%);
- contraindication for MRI;
- body mass index \> 30 kg/m2;
- known locomotor abnormality.
Key Trial Info
Start Date :
June 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2015
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT01520493
Start Date
June 1 2011
End Date
March 1 2015
Last Update
March 7 2018
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Institut universitaire de cardiologie et de pneumologie de Québec (IUCPQ)
Québec, Canada, G1V 4G5
2
Institut universitaire de cardiologie et de pneumologie de Québec
Québec, Canada, G1V 4G5